Pathophysiology of Parkinson's Disease — Chapter 18 | Introduction to Medical Pharmacology

Section 1

The Nigrostriatal Pathway and Dopamine Loss

How degeneration of a specific dopamine-producing nucleus produces the motor features of Parkinson's disease

Parkinson's disease is a progressive neurodegenerative disorder caused by the loss of dopamine-producing neurons in a specific region of the brainstem. Understanding which neurons are lost and where they project explains both why the disease produces its characteristic motor features and why restoring dopamine activity is the central goal of treatment.

The Substantia Nigra Pars Compacta

The dopamine neurons that degenerate in Parkinson's disease are located in the substantia nigra pars compacta, a small nucleus in the midbrain. These neurons send axonal projections to the striatum — the caudate nucleus and putamen — forming the nigrostriatal pathway. This pathway is the primary dopaminergic input to the basal ganglia circuit that controls voluntary movement.

Under normal conditions, dopamine released in the striatum facilitates movement by enabling smooth, coordinated motor output. When the substantia nigra pars compacta loses 70 to 80 percent of its dopamine neurons — the threshold at which symptoms become clinically apparent — this facilitation is lost and motor control deteriorates.

Lewy Bodies

A histological hallmark of Parkinson's disease is the presence of Lewy bodies — intraneuronal inclusions composed primarily of the protein alpha-synuclein — within the surviving neurons of the substantia nigra pars compacta. While their precise role in neurodegeneration remains under study, Lewy bodies are the pathological signature that confirms the diagnosis at autopsy and distinguish Parkinson's disease from other causes of parkinsonism.

Two-panel diagram showing the nigrostriatal dopamine pathway in normal brain and in Parkinson's disease, with substantia nigra pars compacta projecting to the striatum via a solid arrow in the normal panel and a dashed arrow indicating dopamine depletion in the Parkinson's disease panel. — Nigrostriatal pathway: normal dopamine projection from substantia nigra pars compacta to striatum (left) versus the depleted pathway in Parkinson's disease (right). Figure generated by Gemini AI.

Why Symptoms Appear Late

Parkinson's disease is asymptomatic during the early phase of dopamine neuron loss. Motor symptoms emerge only after 70 to 80 percent of nigrostriatal dopamine neurons have been lost. This large reserve capacity explains why the disease is far advanced by the time a patient first presents with tremor or slowness of movement.

Section 2

The Striatal Dopamine-Acetylcholine Balance

How the loss of dopamine creates a relative excess of acetylcholine activity that drives tremor and rigidity

The striatum maintains a functional balance between two opposing neurotransmitter systems: dopamine, which is delivered by the nigrostriatal pathway, and acetylcholine, which is produced by interneurons intrinsic to the striatum itself. This balance governs the quality of motor output. Disrupting it in either direction produces movement problems.

Normal Balance

In the healthy striatum, dopamine exerts an inhibitory modulatory influence that counterbalances the excitatory drive of striatal acetylcholine interneurons. The two systems together regulate the gain of motor circuits — dopamine suppresses unwanted movements while acetylcholine promotes the selection and initiation of intended ones. Together they allow smooth, purposeful motor activity.

Imbalance in Parkinson's Disease

When nigrostriatal dopamine input is lost, the acetylcholine system is left unopposed. The result is a relative excess of cholinergic activity within the striatum, even though acetylcholine production itself has not increased. This imbalance is particularly responsible for the tremor and rigidity seen in Parkinson's disease.

This concept directly explains one of the oldest pharmacological approaches to Parkinson's disease: blocking striatal acetylcholine receptors with anticholinergic drugs reduces the relative cholinergic excess and partially restores the balance. It also explains why drugs that restore dopamine activity — the mainstay of modern treatment — address the imbalance from the opposite direction.

Two-panel balance scale diagram showing equal dopamine and acetylcholine in the normal striatum and a tipped scale with reduced dopamine and excess acetylcholine in Parkinson's disease. — Striatal dopamine-acetylcholine balance: normal equilibrium (left) versus the relative cholinergic excess of Parkinson's disease (right). Figure generated by Gemini AI.

Two Routes to the Same Goal

All pharmacological treatments for Parkinson's disease work by correcting the dopamine-acetylcholine imbalance in the striatum. They do so either by increasing dopaminergic tone (levodopa, dopamine agonists, enzyme inhibitors, amantadine) or by reducing cholinergic tone (anticholinergic drugs). Both strategies move the striatum back toward balance from opposite directions.

Section 3

Cardinal Motor Features of Parkinson's Disease

The four defining motor abnormalities that reflect loss of dopaminergic control of voluntary movement

Parkinson's disease produces four characteristic motor abnormalities that together constitute the classic clinical picture. These features appear when dopamine depletion in the nigrostriatal pathway crosses the symptom threshold. Recognizing them and understanding their mechanistic basis is essential for United States Medical Licensing Examination Step 1.

Feature 1

Tremor

Resting tremor — present at rest, suppressed with voluntary movement
Pill-rolling quality: rhythmic thumb-forefinger motion
Typically 4 to 6 cycles per second
Often the first symptom, most visible feature
Driven by relative cholinergic excess — responds to anticholinergic drugs

Feature 2

Rigidity

Increased resistance to passive limb movement throughout the range of motion
Cogwheel rigidity: ratcheting quality felt during passive flexion and extension
Leadpipe rigidity: uniform resistance without ratcheting
Caused by loss of dopaminergic inhibition of motor tone

Feature 3

Bradykinesia

Slowness of movement initiation and execution
The most disabling feature of Parkinson's disease
Manifests as masked facies, reduced arm swing, micrographia, soft voice
Reflects failure of dopaminergic facilitation of movement initiation
Most responsive to levodopa therapy

Feature 4

Postural Instability

Loss of postural reflexes — impaired ability to correct balance
Typically appears later in the disease course
Leading cause of falls and fall-related injury
Responds poorly to dopaminergic therapy compared to the other features

Step 1 Mnemonic — TRAP

Tremor (resting) · Rigidity (cogwheel) · Akinesia or bradykinesia · Postural instability. The TRAP mnemonic captures all four cardinal features of Parkinson's disease in a testable sequence.

Section 4

Rationale for Pharmacological Intervention

How each drug class addresses the dopamine-acetylcholine imbalance and the limits of what current therapy can achieve

No drug currently available slows or stops the degeneration of substantia nigra pars compacta neurons. All approved pharmacological treatments for Parkinson's disease are symptomatic — they compensate for dopamine deficiency or reduce cholinergic excess, providing functional benefit without altering the underlying disease course. Understanding this distinction is fundamental to counseling patients about realistic treatment expectations.

Strategy 1: Increasing Dopaminergic Tone

The dominant pharmacological strategy in Parkinson's disease is restoring dopamine activity in the striatum. Because dopamine itself cannot cross the blood-brain barrier, drugs must either provide a precursor that crosses and is converted to dopamine inside the brain, mimic dopamine by directly activating its receptors, or extend the activity of whatever dopamine remains by inhibiting the enzymes that break it down.

Levodopa — a dopamine precursor — is the most effective drug in this category and remains the cornerstone of Parkinson's disease pharmacotherapy. Dopamine agonists (pramipexole, ropinirole) activate dopamine receptors directly. Enzyme inhibitors — monoamine oxidase B inhibitors and catechol-O-methyltransferase inhibitors — prolong the effect of levodopa or endogenous dopamine by slowing its metabolism. Amantadine has a modest dopamine-releasing effect in addition to its primary mechanism. Each of these classes is covered in detail in subsequent modules.

Strategy 2: Reducing Cholinergic Tone

Because Parkinson's disease creates a relative cholinergic excess in the striatum, blocking muscarinic receptors with anticholinergic drugs (benztropine, trihexyphenidyl) partially restores the neurotransmitter balance. This strategy is most effective for tremor and rigidity. It has little benefit for bradykinesia — the most disabling feature — and is poorly tolerated in elderly patients due to peripheral anticholinergic adverse effects and cognitive impairment risk.

Symptomatic Treatment Only

All current Parkinson's disease drugs treat symptoms by correcting neurotransmitter imbalance. None has been proven to slow neurodegeneration in the substantia nigra pars compacta. Patients improve functionally, sometimes dramatically, but the underlying disease continues to progress. This explains why motor complications emerge over years of treatment even as individual drug doses are optimized.

Two-panel summary diagram showing drug classes that increase dopamine on the left and anticholinergic drugs that reduce acetylcholine on the right, with a footer stating all strategies correct the striatal imbalance. — Pharmacological strategies for Parkinson's disease: dopamine-enhancing drug classes (left) and acetylcholine-reducing agents (right). Figure generated by Gemini AI.

Suggested References

Author / Organization	Title	Source
Katzung BG, Trevor AJ	Basic and Clinical Pharmacology, 15th edition	McGraw-Hill, 2021
Brunton LL, Knollmann BC	Goodman and Gilman's The Pharmacological Basis of Therapeutics, 13th edition	McGraw-Hill, 2018
Le T, Bhushan V	First Aid for the USMLE Step 1	McGraw-Hill, current edition
Poewe W et al.	Parkinson disease	Nature Reviews Disease Primers, 2017
Obeso JA et al.	Past, present, and future of Parkinson's disease: A special essay on the 200th Anniversary of the Shaking Palsy	Movement Disorders, 2017